-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azeliragon in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azeliragon in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azeliragon in Glioblastoma Multiforme (GBM) Drug Details: Azeliragon is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azeliragon in Refractory Brain Metastasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azeliragon in Refractory Brain Metastasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azeliragon in Refractory Brain Metastasis Drug Details: Azeliragon is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azeliragon in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azeliragon in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azeliragon in Metastatic Adenocarcinoma of The Pancreas Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Odetiglucan in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Odetiglucan in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Odetiglucan in Metastatic Breast Cancer Drug Details: BTH-1677 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SC-291 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SC-291 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SC-291 in Marginal Zone B-cell Lymphoma Drug Details: SC-291...
-
Product Insights
Gliosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Gliosarcoma - Drugs In Development, 2023’, provides an overview of the Gliosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gliosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onureg in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Onureg in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Drug Details: Azacitidine (Onureg) is a pyrimidine analogue...